Comparative Pharmacology
Head-to-head clinical analysis: INDAPAMIDE versus ZAROXOLYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDAPAMIDE versus ZAROXOLYN.
INDAPAMIDE vs ZAROXOLYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indapamide is a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule by blocking the Na-Cl cotransporter, leading to increased excretion of sodium, chloride, and water. It also reduces peripheral vascular resistance through direct vasodilatory effects.
Inhibits sodium reabsorption in the distal convoluted tubule by blocking the thiazide-sensitive sodium-chloride symporter (NCC).
1.25-2.5 mg orally once daily; 2.5 mg is usual maintenance dose; maximum 5 mg/day.
2.5 to 5 mg orally once daily; may increase up to 20 mg daily based on response.
None Documented
None Documented
14–18 hours (terminal elimination half-life); prolonged in renal impairment, supporting once-daily dosing.
Clinical Note
moderateIndapamide + Digoxin
"The risk or severity of adverse effects can be increased when Indapamide is combined with Digoxin."
Clinical Note
moderateIndapamide + Digitoxin
"The risk or severity of adverse effects can be increased when Indapamide is combined with Digitoxin."
Clinical Note
moderateIndapamide + Deslanoside
"The risk or severity of adverse effects can be increased when Indapamide is combined with Deslanoside."
Clinical Note
moderateIndapamide + Acetyldigitoxin
Terminal elimination half-life ranges from 6 to 15 hours (mean ~8 hours) in patients with normal renal function. In renal impairment, half-life is prolonged and accumulation may occur.
Renal excretion (70% unchanged, 23% as glucuronide conjugate); biliary/fecal elimination accounts for <5%.
Primarily renal (approximately 70% as unchanged drug and metabolites) and biliary (approximately 30% as unchanged drug and metabolites into feces).
Category A/B
Category C
Thiazide-like Diuretic
Thiazide-like Diuretic
"The risk or severity of adverse effects can be increased when Indapamide is combined with Acetyldigitoxin."